MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - Commentary
Mult Scler
.
2020 Mar;26(3):276-278.
doi: 10.1177/1352458519895236.
Epub 2019 Dec 17.
Author
Kazuo Fujihara
1
Affiliation
1
Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, and Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan.
PMID:
31842707
DOI:
10.1177/1352458519895236
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Antibodies
Humans
Myelin-Oligodendrocyte Glycoprotein
Neuromyelitis Optica*
Substances
Antibodies
Myelin-Oligodendrocyte Glycoprotein